Palbociclib use with grade 3 neutropenia in hormone receptor-positive metastatic breast cancer.

Ahrong HamMin Hwan KimGun Min KimJee Hung KimJee Ye KimHyung Seok ParkSeho ParkYoung Up ChoByeong Woo ParkSeung Il KimJoo Hyuk Sohn

Published in: Breast cancer research and treatment (2020)

Thus, omitting palbociclib dose modification with afebrile grade 3 neutropenia is safe and tolerable without febrile neutropenia events. This scheme could be useful to avoid unnecessary reductions in palbociclib doses in future practice.

Keyphrases

metastatic breast cancer
chemotherapy induced
primary care
healthcare
current status
quality improvement